USANA Health Sciences, Inc. announced its financial results for the second quarter of 2022, including a 14% decline in active customers from the previous year’s quarter, totaling 559,000. Net sales for the company were also down (-21%) to $264 million, as compared to $337 million during the second quarter of 2021.
Asia Pacific continued to be the company’s top-earning region, with $217 million in net sales, a 22% decline from last year’s quarter. The Americas and Europe region saw a 19% decline over the previous quarter, with $47 million in net sales.
Second quarter diluted EPS totaled $1, down from $1.87 during the second quarter of last year.
“During the quarter, we streamlined our associate onboarding program and provided associates with additional tools to help them more efficiently and effectively setup and operate their businesses,” Guest said. “Our team also launched improvements to our China shopping app to further improve the online shopping experience in that market. Although it takes time to recapture momentum, we are confident these strategies will deliver long-term growth.”
The company closed the quarter with $230 million in cash and cash equivalents and holds to its net sales and earnings per share outlook for fiscal year 2022, expecting a consolidated net sales range of $1.015-$10.65 billion and a diluted EPS ranging between $3.85-$4.45.
